BC Week In Review | Apr 14, 2017
Company News

2-BBB Medicines, TTY Biopharm deal

The companies formed a joint venture in Taiwan to develop and commercialize 2-BBB’s multiple sclerosis candidate 2B3-201 . 2-BBB will grant the JV exclusive rights to 2B3-201 and will receive a 33.3% stake in the JV;...
BC Week In Review | Mar 31, 2017
Company News

2-BBB, Oncology Venture deal

2-BBB granted Oncology Venture exclusive, worldwide rights to develop and commercialize 2X-111 (formerly 2B3-101) to treat cancer. The pegylated liposomal doxorubicin conjugated with glutathione has completed a Phase II trial to treat solid tumors, including...
BC Extra | Jul 1, 2014
Financial News

to-BBB raises EUR 10M in series C

Drug delivery company to-BBB technologies B.V. (Leiden, the Netherlands) raised EUR 10 million ($13.7 million) in a series C round from new and existing investors. The company's investors include Aescap Venture; Antea Participaties; Jonghoud International;...
BC Week In Review | Oct 14, 2013
Clinical News

2B3-101: Phase I/IIa data

Data from 25 patients with brain metastases from solid tumors or recurrent malignant glioma in the Phase I portion of an open-label, dose-escalation, international Phase I/IIa trial showed that 5-60 mg/m 2 doses of IV...
BC Week In Review | Sep 2, 2013
Clinical News

2B3-101: Phase I/IIa ongoing

to-BBB began the Phase IIa portion of an open-label, dose-escalation, European Phase I/IIa trial to evaluate IV 2B3-101 in about 82 patients with recurrent malignant glioma and patients with brain metastasis from breast cancer, small...
BC Innovations | May 30, 2013
Tools & Techniques

Optimizing transferrin-mediated transcytosis

Researchers at the California Institute of Technology have shown how modulating the transferrin content on gold nanoparticles can optimize their delivery into the brain via the transferrin receptor . 1 The group now needs to determine...
BC Innovations | Oct 4, 2012
Cover Story

Slipping past P glycoprotein

NIH researchers have shown that sphingosine 1-phosphate receptor agonists such as Novartis AG 's Gilenya fingolimod could transiently reduce P glycoprotein -mediated drug efflux and enhance drug delivery to the brain. 1 The group at...
BC Week In Review | Jul 4, 2011
Clinical News

2B3-101: Phase I/IIa started

to-BBB began an open-label, dose-escalation, Dutch Phase I/IIa trial to evaluate 2B3-101 in about 40 patients. The trial includes an extension phase in 10 patients with brain metastases of breast cancer. to-BBB technologies B.V. , Leiden,...
BC Innovations | Nov 4, 2010
Cover Story

LAMbasting brain cancer

Approved therapies to treat brain cancer are not entirely tumor cell-specific and thus can have severe dose-limiting toxicities that decrease their effectiveness. A team of U.S. and German researchers thinks it has overcome this problem...
BC Week In Review | Jun 21, 2010
Clinical News

2B3-101 regulatory update

The COMP issued a positive opinion to grant Orphan Drug designation to to-BBB's 2B3-101 to treat glioma. The liposomal doxorubicin formulation, which is conjugated with glutathione to enhance delivery across the blood-brain barrier, is expected...
Items per page:
1 - 10 of 12